UT Health San Antonio (Long School of Medicine)
Infectious Disease fellowship · San Antonio, TX · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is The University of Texas at San Antonio Health Science Center's research in infectious disease, which the program shares with other departments and affiliated hospitals.
About The University of Texas at San Antonio Health Science Centerinstitution-wide infectious disease research
Infectious Disease publications from The University of Texas at San Antonio Health Science Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
50
works per year
38th of 71 infectious disease fellowship programs
-19.8%
2-year growth
21st of 71 infectious disease fellowship programs
33.1%
in top 10% of field (works before 2025)
7th of 67 infectious disease fellowship programs
57.3%
cited above world average
13th of 67 infectious disease fellowship programs
Works per year · * 2026 so far
Infectious Diseases · 242
Infectious Disease research topics at The University of Texas at San Antonio Health Science Center
Papers in the window; each links to the list on OpenAlex.
- Antifungal resistance and susceptibility 68
- COVID-19 Clinical Research Studies 37
- SARS-CoV-2 and COVID-19 Research 36
- Tuberculosis Research and Epidemiology 30
- HIV/AIDS Research and Interventions 20
- Clostridium difficile and Clostridium perfringens research 11
- Infection Control in Healthcare 8
- Antimicrobial Resistance in Staphylococcus 6
Most cited at The University of Texas at San Antonio Health Science Center since 2024
All infectious disease papers there on OpenAlex
- Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASMOliver A. Cornely et al. · The Lancet Infectious Diseases · 2025 · PubMed · cited 444
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal diseaseMartin Hoenigl et al. · Clinical Microbiology Reviews · 2024 · PubMed · cited 160
- Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b studyJohan A. Maertens et al. · The Lancet Infectious Diseases · 2025 · PubMed · cited 83
- Risk-stratified treatment for drug-susceptible pulmonary tuberculosisVincent K. Chang et al. · Nature Communications · 2024 · PubMed · cited 38
- A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based systemFrancesco Costacurta et al. · PLoS Pathogens · 2024 · PubMed · cited 26
- Candida auris MIC testing by EUCAST and clinical and laboratory standards institute broth microdilution, and gradient diffusion strips; to be or not to be amphotericin B resistant?Maiken Cavling Arendrup et al. · Clinical Microbiology and Infection · 2024 · PubMed · cited 22
- Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis StrategiesJo‐Anne H. Young et al. · Open Forum Infectious Diseases · 2024 · PubMed · cited 19
- Mitochondrial Transplantation Promotes Protective Effector and Memory CD4 + T Cell Response During Mycobacterium Tuberculosis Infection and Diminishes Exhaustion and Senescence in Elderly CD4 + T cellsColwyn Ansel Headley et al. · Advanced Science · 2024 · PubMed · cited 18
- A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and RezafunginAna Espinel‐Ingroff et al. · Journal of Fungi · 2024 · PubMed · cited 18
- Universal digital high-resolution melting for the detection of pulmonary mold infectionsTyler Goshia et al. · Journal of Clinical Microbiology · 2024 · PubMed · cited 18